Inovio Pharmaceuticals Inc (NASDAQ:INO) reported that it has finalized collaborative research agreements with the Wistar Institute for therapeutic and preventive DNA-based immunotherapy products and applications for cancers and infectious diseases advanced by David B. Weiner, Ph.D., and Wistar lab. The company will possess the exclusive right to respective new intellectual, in-license property advanced in this collaboration.

The expert view

Dr. J. Joseph Kim, the CEO and President of Inovio, said that this new deal with Wistar begins a whole new chapter of company’s R&D leadership in DNA-based immunotherapies. He congratulated Dr. Weiner for his multiple new positions at Wistar and the considerably expanded laboratory and resources accessible to him to continue working on his life’s passion. The CEO added that they look forward to a fruitful and long association with the Wistar to continue developing innovative DNA-based immunotherapies as well as monoclonal antibody technology.

The contributions

The Wistar Institute boasts a storied tradition of global leadership, commercialization and training, and accomplishment in the field of immune therapies and vaccines. Their technology has achieved significant health developments including the discoveries of vaccines against rabies, rubella, and rotavirus. Wistar technology led in the development of varicella, zoster and hepatitis A vaccines along with revolutionary products for the treatment or diagnosis of heart, autoimmune, and other infectious diseases.

The past experience

Dr. Weiner is a leader in the field of DNA vaccines and immunotherapies and one of the founders of VGX Pharmaceuticals, which turned into Inovio Pharmaceuticals after a corporate merger. He is Chairman of Inovio’s Scientific Advisory Board and also a member of company’s Board of Directors. As the Wistar’s Executive VP and Director of its newly set Vaccine Center, Dr. Weiner is set to have the resources as well as mandate to considerably expand Wistar’s immunology research plans and apply translational expertise to fill the gap between clinical and research application. He will also contribute in tumor immunology-based research to support the ongoing work and objective of Wistar.

Previous articleKey Updates From Kite Pharma Inc (NASDAQ:KITE)
Next articleVitae Pharmaceuticals Inc (NASDAQ:VTAE) Psoriasis Drug Achieves Success In Mid-stage Trial
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg,,, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.